Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.

Novartis researchers aim to improve the lives of patients with osteoarthritis.

Novartis-Harvard team identifies a new type of cell that is key to the disease.

Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.

Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.

A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.

Targeting inflammation to fight cancer is a new approach with a long history.

Novartis is developing an experimental drug for weight loss.

Learn how Novartis researchers are working to outsmart tumors.

Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.